A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

1.

Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021;96(2):59–77. https://doi.org/10.1212/WNL.0000000000011153.CrossRefPubMedPubMedCentral

2.

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. https://doi.org/10.3389/fneur.2020.00501.CrossRefPubMedPubMedCentral

3.

Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019;27:412–8. https://doi.org/10.1016/j.msard.2018.12.002.CrossRefPubMed

4.

Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, Aoki M. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e640. https://doi.org/10.1212/NXI.0000000000000640.CrossRefPubMedPubMedCentral

5.

Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727. https://doi.org/10.1038/s41598-020-73882-8.CrossRefPubMedPubMedCentral

6.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12. https://doi.org/10.1016/S0140-6736(04)17551-X.CrossRefPubMed

7.

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7. https://doi.org/10.1084/jem.20050304.CrossRefPubMedPubMedCentral

8.

Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535–44. https://doi.org/10.1016/S1474-4422(12)70133-3.CrossRefPubMedPubMedCentral

9.

Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–94. https://doi.org/10.1007/s00415-017-8596-7.CrossRefPubMedPubMedCentral

10.

Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72. https://doi.org/10.1016/j.msard.2018.07.025.CrossRefPubMed

11.

Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS. Aquaporin-targeted therapeutics: state-of-the-field. Adv Exp Med Biol. 2017;969:239–50. https://doi.org/10.1007/978-94-024-1057-0_16.CrossRefPubMedPubMedCentral

12.

Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–74. https://doi.org/10.1016/j.tins.2015.04.003.CrossRefPubMedPubMedCentral

13.

Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008;10(1):55–66. https://doi.org/10.1007/s11940-008-0007-z.CrossRefPubMed

14.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–32. https://doi.org/10.1111/j.1468-1331.2010.03066.x.CrossRefPubMed

15.

Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–34. https://doi.org/10.1212/WNL.0b013e31823dc535.

16.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–16. https://doi.org/10.1002/ana.24554.CrossRefPubMed

17.

Qin C, Tao R, Zhang SQ, Chen B, Chen M, Yu HH, et al. Predictive factors of resistance to high-dose steroids therapy in acute attacks of neuromyelitis optica spectrum disorder. Front Neurol. 2020;11:585471. https://doi.org/10.3389/fneur.2020.585471.CrossRefPubMedPubMedCentral

18.

Correia I, Ribeiro JJ, Isidoro L, Batista S, Nunes C, Macario C, et al. Plasma exchange in severe acute relapses of multiple sclerosis - results from a Portuguese cohort. Mult Scler Relat Disord. 2018;19:148–52. https://doi.org/10.1016/j.msard.2017.12.001.CrossRefPubMed

19.

Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58(1):143–6. https://doi.org/10.1212/wnl.58.1.143.CrossRefPubMed

20.

Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300. https://doi.org/10.1212/WNL.0b013e318207b1f6.CrossRefPubMedPubMedCentral

21.

Oshiro A, Nakamura S, Tamashiro K, Fujihara K. Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis. No To Hattatsu. 2016;48(3):199–203.PubMed

22.

Song W, Qu Y, Huang X. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. Int Ophthalmol. 2019;39(11):2477–83. https://doi.org/10.1007/s10792-019-01090-z.CrossRefPubMed

23.

Aungsumart S, Apiwattanakul M. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature. Mult Scler Relat Disord. 2017;13:93–7. https://doi.org/10.1016/j.msard.2017.02.015.CrossRefPubMed

24.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e504. https://doi.org/10.1212/NXI.0000000000000504.CrossRefPubMedPubMedCentral

25.

Bonnan M, Valentino R, Debeugny S, Merle H, Ferge JL, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346–51. https://doi.org/10.1136/jnnp-2017-316286.CrossRefPubMed

26.

Huang X, Wu J, Xiao Y, Zhang Y. Timing of plasma exchange for neuromyelitis optica spectrum disorders: a meta-analysis. Mult Scler Relat Disord. 2021;48:102709. https://doi.org/10.1016/j.msard.2020.102709.CrossRefPubMed

27.

Sergent SR, Ashurst JV. Plasmapheresis. [Updated 2022 Jul 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560566/.

28.

Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22–32. https://doi.org/10.1016/j.msard.2019.05.011.CrossRefPubMed

29.

Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659–66. https://doi.org/10.1212/WNL.0b013e31822a2780.CrossRefPubMed

30.

Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645–56. https://doi.org/10.1212/WNL.0000000000009245.CrossRefPubMed

31.

Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24(1):219–26. https://doi.org/10.1111/ene.13186.CrossRefPubMed

32.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–30. https://doi.org/10.1001/jamaneurol.2013.5699.CrossRefPubMed

33.

Zhang M, Zhang C, Bai P, Xue H, Wang G. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg. 2017;117(3):695–702. https://doi.org/10.1007/s13760-017-0795-6.CrossRefPubMed

34.

Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329–39. https://doi.org/10.1177/1352458515587752.CrossRefPubMed

35.

Qiu W, Kermode AG, Li R, Dai Y, Wang Y, Wang J, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci. 2015;22(7):1178–82. https://doi.org/10.1016/j.jocn.2015.01.028.CrossRefPubMed

36.

Elsone L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler. 2014;20(11):1533–40. https://doi.org/10.1177/1352458514525870.CrossRefPubMed

37.

Xu Y, Wang Q, Ren HT, Qiao L, Zhang Y, Fei YY, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci. 2016;370:224–8. https://doi.org/10.1016/j.jns.2016.09.035.CrossRefPubMed

38.

• Magdalena C, Clarissa A, Sutandi N. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: a systematic review and meta-analysis. Innov Clin Neurosci. 2022;19(4–6):51–64. A contemporary meta-analyses comparing conventional oral immunosuppressive agents to rituximab in NMOSD.

39.

Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003–9. https://doi.org/10.1007/s00415-017-8590-0.CrossRefPubMed

40.

Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192–7. https://doi.org/10.1016/j.jns.2017.12.034.CrossRefPubMed

41.

McWilliam M, Khan U. Azathioprine and the neurologist. Pract Neurol. 2020;20(1):69–74. https://doi.org/10.1136/practneurol-2018-002161.CrossRefPubMed

42.

Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128–33. https://doi.org/10.1001/archneurol.2009.175.CrossRefPubMed

43.

Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71(11):1372–8. https://doi.org/10.1001/jamaneurol.2014.2057.CrossRefPubMed

44.

Huang Q, Wang J, Zhou Y, Yang H, Wang Z, Yan Z, et al. Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol. 2018;9:2066. https://doi.org/10.3389/fimmu.2018.02066.CrossRefPubMedPubMedCentral

45.

Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, et al. The Efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol. 2016;39(2):81–7. https://doi.org/10.1097/WNF.0000000000000131.CrossRefPubMed

46.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377–84. https://doi.org/10.1177/1352458516678474.CrossRefPubMed

47.

Wang Y, Ma J, Chang H, Zhang X, Yin L. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord. 2021;55:103181. https://doi.org/10.1016/j.msard.2021.103181.CrossRefPubMed

48.

Enriquez CAG, Espiritu AI, Pasco PMD. Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review. J Neuroimmunol. 2019;332:126–34. https://doi.org/10.1016/j.jneuroim.2019.04.007.CrossRefPubMed

49.

Ramanathan RS, Malhotra K, Scott T. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol. 2014;14:51. https://doi.org/10.1186/1471-2377-14-51.CrossRefPubMedPubMedCentral

50.

Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84(8):918–21. https://doi.org/10.1136/jnnp-2012-304774.CrossRefPubMed

51.

Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis. 2011;2011:961702. https://doi.org/10.4061/2011/961702.CrossRefPubMedPubMedCentral

52.

Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52(9):969–72. https://doi.org/10.2169/internalmedicine.52.7885.CrossRefPubMed

53.

Wang L, Liu K, Tan X, Zhou L, Zhang Y, Liu X, et al. Remedial effect of intravenous cyclophosphamide in corticosteroid-refractory patients in the acute phase of neuromyelitis optica spectrum disorder-related optic neuritis. Front Neurol. 2020;11:612097. https://doi.org/10.3389/fneur.2020.612097.CrossRefPubMed

54.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019;19(1):5–20. https://doi.org/10.1136/practneurol-2018-001899.CrossRefPubMed

55.

Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, et al. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci. 2017;22:18. https://doi.org/10.4103/1735-1995.200275.CrossRefPubMedPubMedCentral

56.

Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, et al. Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study. J Neurol. 2016;263(9):1727–35. https://doi.org/10.1007/s00415-016-8188-y.CrossRefPubMed

57.

Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342–8. https://doi.org/10.1001/jamaneurol.2016.1637.CrossRefPubMed

58.

Wang Y, Chang H, Zhang X, Yin L. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord. 2021;50:102843. https://doi.org/10.1016/j.msard.2021.102843.CrossRefPubMed

59.

Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110–7. https://doi.org/10.1001/jamaneurol.2013.3071.CrossRefPubMed

60.

Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, et al. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Mult Scler Relat Disord. 2022;60:103730. https://doi.org/10.1016/j.msard.2022.103730.CrossRefPubMed

61.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. https://doi.org/10.1016/S1474-4422(20)30066-1.CrossRefPubMed

62.

Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Variable results after rituximab in neuromyelitis optica. J Neurol Sci. 2012;317(1–2):103–5. https://doi.org/10.1016/j.jns.2012.02.017.CrossRefPubMed

63.

Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e61. https://doi.org/10.1212/NXI.0000000000000061.CrossRefPubMedPubMedCentral

64.

Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412–20. https://doi.org/10.1001/archneurol.2011.154.CrossRefPubMed

65.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2016;22(7):955–9. https://doi.org/10.1177/1352458515602337.CrossRefPubMed

66.

Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262(10):2329–35. https://doi.org/10.1007/s00415-015-7852-y.CrossRefPubMed

67.

Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018;265(4):917–25. https://doi.org/10.1007/s00415-018-8771-5.CrossRefPubMed

68.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310–5. https://doi.org/10.1212/WNL.0b013e3182152881.CrossRefPubMed

69.

Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009;15(8):1006–8. https://doi.org/10.1177/1352458509106512.CrossRefPubMed

70.

Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225–30. https://doi.org/10.1177/1352458511404586.CrossRefPubMed

71.

Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013;324(1–2):38–9. https://doi.org/10.1016/j.jns.2012.09.024.CrossRefPubMed

72.

Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989–95. https://doi.org/10.1001/jamaneurol.2015.1276.CrossRefPubMed

73.

Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019;19(1):36. https://doi.org/10.1186/s12883-019-1261-2.CrossRefPubMedPubMedCentral

74.

Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2020;38:101868. https://doi.org/10.1016/j.msard.2019.101868.CrossRefPubMed

75.

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174(4):255–64. https://doi.org/10.1016/j.neurol.2017.11.005.CrossRefPubMed

76.

Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115–22. https://doi.org/10.1007/s00415-018-8812-0.CrossRefPubMedPubMedCentral

77.

Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701–6. https://doi.org/10.1073/pnas.1017385108.CrossRefPubMedPubMedCentral

78.

Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5(12):107. https://doi.org/10.3390/jcm5120107.CrossRefPubMedPubMedCentral

79.

Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213–22. https://doi.org/10.1124/jpet.110.168062.CrossRefPubMed

80.

Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall’Acqua W, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol. 2011;155(4):426–37. https://doi.org/10.1111/j.1365-2141.2011.08857.x.CrossRefPubMed

81.

Gallagher S, Turman S, Yusuf I, Akhgar A, Wu Y, Roskos LK, et al. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice. Int Immunopharmacol. 2016;36:205–12. https://doi.org/10.1016/j.intimp.2016.04.035.CrossRefPubMed

82.

Gallagher S, Yusuf I, McCaughtry TM, Turman S, Sun H, Kolbeck R, et al. MEDI-551 treatment effectively depletes B cells and reduces serum titers of autoantibodies in mice transgenic for Sle1 and human CD19. Arthritis Rheumatol. 2016;68(4):965–76. https://doi.org/10.1002/art.39503.CrossRefPubMed

83.

Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259–64. https://doi.org/10.1007/s40265-020-01370-4.CrossRefPubMedPubMedCentral

84.

Yan L, Wang B, She D, Mitchell B, Criste R, Cimbora D, et al. Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders. Br J Clin Pharmacol. 2022;88(8):3803–12. https://doi.org/10.1111/bcp.15332.CrossRefPubMed

85.

•• Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–63. https://doi.org/10.1016/S0140-6736(19)31817-3. Phase III randomized controlled trial of inebilizumab in NMOSD compared to placebo, stopped early due to reaching efficacy stopping rules. Truly placebo-controlled, widely recruited trial with, intended treatment phase period of only 6 months to avoid protracted risk of relapse.CrossRefPubMed

86.

Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Mult Scler. 2022;28(6):925–32. https://doi.org/10.1177/13524585211047223.CrossRefPubMed

87.

Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, et al. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022;57:103356. https://doi.org/10.1016/j.msard.2021.103356.CrossRefPubMed

88.

Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, et al. Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e978. https://doi.org/10.1212/NXI.0000000000000978.

89.

Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, et al. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine. 2022;86:104321. https://doi.org/10.1016/j.ebiom.2022.104321.CrossRefPubMedPubMedCentral

90.

Flanagan EP, Levy M, Katz E, Cimbora D, Drappa J, Mealy MA, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord. 2022;57:103352. https://doi.org/10.1016/j.msard.2021.103352.CrossRefPubMed

91.

Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841. https://doi.org/10.1212/NXI.0000000000000841.

92.

Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. https://doi.org/10.1002/eji.201040391.CrossRefPubMed

93.

Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review. Int J Neurosci. 2016;126(12):1051–60. https://doi.org/10.3109/00207454.2016.1163550.CrossRefPubMed

94.

Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311. https://doi.org/10.1212/NXI.0000000000000311.CrossRefPubMed

95.

Takeshita Y, Fujikawa S, Serizawa K, Fujisawa M, Matsuo K, Nemoto J, et al. New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1076. https://doi.org/10.1212/NXI.0000000000001076.

96.

Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254–66. https://doi.org/10.7150/ijbs.4679.CrossRefPubMedPubMedCentral

97.

Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010;10(3):167–84. https://doi.org/10.1111/j.1533-2500.2010.00367.x.CrossRefPubMed

98.

Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res. 2000;879(1–2):216–25. https://doi.org/10.1016/s0006-8993(00)02807-9.CrossRefPubMed

99.

Serizawa K, Tomizawa-Shinohara H, Yasuno H, Yogo K, Matsumoto Y. Anti-IL-6 receptor antibody inhibits spontaneous pain at the pre-onset of experimental autoimmune encephalomyelitis in mice. Front Neurol. 2019;10:341. https://doi.org/10.3389/fneur.2019.00341.CrossRefPubMedPubMedCentral

100.

Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443–52. https://doi.org/10.1177/1352458510379247.CrossRefPubMed

101.

Barros PO, Cassano T, Hygino J, Ferreira TB, Centuriao N, Kasahara TM, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480–9. https://doi.org/10.1111/cei.12733.CrossRefPubMed

102.

Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013;8(4):e61835. https://doi.org/10.1371/journal.pone.0061835.CrossRefPubMedPubMedCentral

103.

Icoz S, Tuzun E, Kurtuncu M, Durmus H, Mutlu M, Eraksoy M, et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 2010;120(1):71–5. https://doi.org/10.3109/00207450903428970.CrossRefPubMed

104.

Wei Y, Chang H, Li X, Wang H, Du L, Zhou H, et al. Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6. NeuroImmunoModulation. 2018;25(4):215–24. https://doi.org/10.1159/000494976.CrossRefPubMed

105.

Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Sawai S, et al. Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica. Clin Chim Acta. 2017;469:144–9. https://doi.org/10.1016/j.cca.2017.03.006.CrossRefPubMed

106.

Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181–3. https://doi.org/10.1016/j.cca.2013.03.020.CrossRefPubMed

107.

Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256(12):2082–4. https://doi.org/10.1007/s00415-009-5274-4.CrossRefPubMed

108.

Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, et al. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. NeuroImmunoModulation. 2012;19(5):304–8. https://doi.org/10.1159/000339302.CrossRefPubMed

109.

•• Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–24. https://doi.org/10.1056/NEJMoa1901747. Phase III randomized placebo-controlled trial of satralizumab add on to immunosuppressive therapy in NMOSD.

110.

Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203–7. https://doi.org/10.1038/nbt.1691.CrossRefPubMed

111.

•• Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–12. https://doi.org/10.1016/S1474-4422(20)30078-8. Phase III randomized placebo-controlled trial of satralizumab immunosuppressive therapy in NMOSD. CrossRefPubMedPubMedCentral

112.

Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. https://doi.org/10.1212/NXI.0000000000200071.

113.

Duchow A, Bellmann-Strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021;11(1):49–59. https://doi.org/10.2217/nmt-2020-0046.CrossRefPubMed

114.

Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2021;19(2):220–32. https://doi.org/10.2174/1570159X18666200429010825.CrossRefPubMedPubMedCentral

115.

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. https://doi.org/10.1016/j.msard.2022.104025.CrossRefPubMed

116.

Hoffmann-La Roche Limited. https://www.rochecanada.com/PMs/Actemra/Actemra_PM_E.pdf. Date of initial authorization 30 Apr 2010 [Amended 20 June 2023]. Accessed 19 March 2023.

117.

Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013;23(4):827–31. https://doi.org/10.1007/s10165-012-0715-9.CrossRefPubMed

118.

Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70(3):390–3. https://doi.org/10.1001/jamaneurol.2013.668.CrossRefPubMed

119.

Lauenstein AS, Stettner M, Kieseier BC, Lensch E. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep. 2014;2014:bcr2013202939. https://doi.org/10.1136/bcr-2013-202939.CrossRefPubMedPubMedCentral

120.

Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, et al. Interferon-beta-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol. 2014;14:247. https://doi.org/10.1186/s12883-014-0247-3.CrossRefPubMedPubMedCentral

121.

Breu M, Glatter S, Hoftberger R, Freilinger M, Kircher K, Kasprian G, et al. Two cases of pediatric AQP4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab. Neuropediatrics. 2019;50(3):193–6. https://doi.org/10.1055/s-0039-1684004.CrossRefPubMed

122.

Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report. Mod Rheumatol. 2016;26(2):294–6. https://doi.org/10.3109/14397595.2013.861333.CrossRefPubMed

123.

Marino A, Narula S, Lerman MA. First Pediatric patient with neuromyelitis optica and sjogren syndrome successfully treated with tocilizumab. Pediatr Neurol. 2017;73:e5–6. https://doi.org/10.1016/j.pediatrneurol.2017.05.015.CrossRefPubMed

124.

Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394–7. https://doi.org/10.1001/jamaneurol.2013.1246.CrossRefPubMed

125.

Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, Meca Lallana V, Arocas Casan V, Iniesta Martinez F, et al. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022;37(3):178–83. https://doi.org/10.1016/j.nrleng.2018.12.021.CrossRefPubMed

126.

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stogbauer F, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756–63. https://doi.org/10.1001/jamaneurol.2015.0533.CrossRefPubMed

127.

Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–6. https://doi.org/10.1212/WNL.0000000000000317.CrossRefPubMedPubMedCentral

128.

Rigal J, Pugnet G, Ciron J, Lepine Z, Biotti D. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Disord. 2020;46:102483. https://doi.org/10.1016/j.msard.2020.102483.CrossRefPubMed

129.

Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;39:101920. https://doi.org/10.1016/j.msard.2019.101920.CrossRefPubMed

130.

Du C, Zeng P, Han JR, Zhang TX, Jia D, Shi FD, et al. Early initiation of tocilizumab treatment against moderate-to-severe myelitis in neuromyelitis optica spectrum disorder. Front Immunol. 2021;12:660230. https://doi.org/10.3389/fimmu.2021.660230.CrossRefPubMedPubMedCentral

131.

Xie Q, Zheng T, Sun M, Sun J, Wang M. A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;45:102421. https://doi.org/10.1016/j.msard.2020.102421.CrossRefPubMed

132.

Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401. https://doi.org/10.1016/S1474-4422(20)30070-3.CrossRefPubMedPubMedCentral

133.

Stathopoulos P, Dalakas MC. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. Expert Rev Clin Immunol. 2022;18(9):933–45. https://doi.org/10.1080/1744666X.2022.2105205.CrossRefPubMed

134.

Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125(Pt 7):1450–61. https://doi.org/10.1093/brain/awf151.CrossRefPubMed

135.

Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69(24):2221–31. https://doi.org/10.1212/01.WNL.0000289761.64862.ce.CrossRefPubMed

136.

Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012;109(4):1245–50. https://doi.org/10.1073/pnas.1109980108.CrossRefPubMed

137.

Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(Pt 2):349–61. https://doi.org/10.1093/brain/awp309.CrossRefPubMedPubMedCentral

138.

Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2018;15(1):294. https://doi.org/10.1186/s12974-018-1333-z.CrossRefPubMedPubMedCentral

139.

•• Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–25. https://doi.org/10.1056/NEJMoa1900866. Phase III randomized controlled trial of eculizumab in NMOSD compared to placebo.CrossRefPubMed

140.

Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder. Front Neurol. 2021;12:696387. https://doi.org/10.3389/fneur.2021.696387.CrossRefPubMedPubMedCentral

141.

Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088–98. https://doi.org/10.1002/ana.26049.CrossRefPubMedPubMedCentral

142.

Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021;47:102641. https://doi.org/10.1016/j.msard.2020.102641.CrossRefPubMed

143.

Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2022;28(3):480–6. https://doi.org/10.1177/13524585211038291.CrossRefPubMed

144.

Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, et al. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord. 2021;50:102849. https://doi.org/10.1016/j.msard.2021.102849.CrossRefPubMed

145.

Chatterton S, Parratt JDE, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol. 2022;13:951423. https://doi.org/10.3389/fneur.2022.951423.CrossRefPubMedPubMedCentral

146.

Digala L, Katyal N, Narula N, Govindarajan R. Eculizumab in the treatment of aquaporin-4 seronegative neuromyelitis optica spectrum disorder: a case report. Front Neurol. 2021;12:660741. https://doi.org/10.3389/fneur.2021.660741.CrossRefPubMedPubMedCentral

147.

Saab G, Munoz DG, Rotstein DL. Chronic cognitive impairment in AQP4+ NMOSD with improvement in cognition on eculizumab: a report of two cases. Front Neurol. 2022;13:863151. https://doi.org/10.3389/fneur.2022.863151.CrossRefPubMedPubMedCentral

148.

•• Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, et al. Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Neurol Ther. 2022;11(1):123–35. https://doi.org/10.1007/s40120-021-00295-8. An elegant meta-analysis with the goal of comparing current pivotal trials in NMOSD to distinguish treatment response between them within limits of such an analysis.CrossRefPubMed

149.

Shi M, Chu F, Jin T, Zhu J. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD. CNS Neurosci Ther. 2022;28(7):981–91. https://doi.org/10.1111/cns.13836.CrossRefPubMedPubMedCentral

150.

McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–7. https://doi.org/10.15585/mmwr.mm6627e1.CrossRefPubMedPubMedCentral

151.

•• Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053–68. https://doi.org/10.1002/ana.26626. Randomized controlled trial of ravulizumab in NMOSD compared to placebo. PREVENT trial placebo group used as historial controls, with NO relapses in the treatment group seen during the trial.CrossRefPubMed

152.

Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701. https://doi.org/10.1080/1744666X.2022.2082946.CrossRefPubMed

153.

Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–9. https://doi.org/10.1182/blood-2018-09-876805.CrossRefPubMedPubMedCentral

154.

Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–9. https://doi.org/10.1182/blood-2018-09-876136.CrossRefPubMedPubMedCentral

155.

Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60–7. https://doi.org/10.1016/S1474-4422(20)30392-6.CrossRefPubMed

156.

Shimizu Y, Fujihara K, Ohashi T, Nakashima I, Yokoyama K, Ikeguch R, et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler. 2016;22(11):1413–20. https://doi.org/10.1177/1352458515583376.CrossRefPubMed

157.

Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. J Neurol. 2022;269(10):5674–81. https://doi.org/10.1007/s00415-022-11241-5.CrossRefPubMedPubMedCentral

158.

Collongues N, Alves Do Rego C, Bourre B, Biotti D, Marignier R, da Silva AM, et al. Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder. Neurology. 2021;96(15):e2006–15. https://doi.org/10.1212/WNL.0000000000011744.CrossRefPubMed

159.

Belizna C, Meroni PL, Shoenfeld Y, Devreese K, Alijotas-Reig J, Esteve-Valverde E, et al. In utero exposure to azathioprine in autoimmune disease. Where do we stand? Autoimmun Rev. 2020;19(9):102525. https://doi.org/10.1016/j.autrev.2020.102525.CrossRefPubMed

160.

Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187–207. https://doi.org/10.1002/bdra.23003.CrossRefPubMed

161.

Asgari N, Henriksen TB, Petersen T, Lillevang ST, Weinshenker BG. Pregnancy outcomes in a woman with neuromyelitis optica. Neurology. 2014;83(17):1576–7. https://doi.org/10.1212/WNL.0000000000000911.CrossRefPubMed

162.

Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet. 2015;4(2):42–55. https://doi.org/10.1055/s-0035-1556743.CrossRefPubMedPubMedCentral

163.

Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol. 2021;23(4):11. https://doi.org/10.1007/s11940-021-00666-4.CrossRefPubMedPubMedCentral

164.

Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e734. https://doi.org/10.1212/NXI.0000000000000734.CrossRefPubMedPubMedCentral

165.

Database DaL: Rituximab https://www.ncbi.nlm.nih.gov/books/NBK501798/ (2023). Accessed April 4 2023

166.

Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–506. https://doi.org/10.1182/blood-2010-07-295444.CrossRefPubMed

167.

Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:271363. https://doi.org/10.1155/2008/271363.CrossRefPubMedPubMedCentral

168.

Morales E, Galindo A, Garcia L, Villalain C, Alonso M, Gutierrez E, et al. Eculizumab in early-stage pregnancy. Kidney Int Rep. 2020;5(12):2383–7. https://doi.org/10.1016/j.ekir.2020.09.045.CrossRefPubMedPubMedCentral

169.

Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019;32(1):17–25. https://doi.org/10.1007/s40620-018-0517-z.CrossRefPubMed

170.

Soliris product monograph. https://alexion.com/Documents/Canada/Product-Monograph-Soliris-English-20Aug2018.aspx Accessed March 19 2023.

171.

•• Newsome SD, Cross AH, Fox RJ, Halper J, Kanellis P, Bebo B, et al. COVID-19 in patients with neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disease in North America: from the COViMS Registry. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1057. https://doi.org/10.1212/NXI.0000000000001057. A study on risk factors in the setting of COVID-19 and their relation to NMOSD.

172.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780–9. https://doi.org/10.1002/ana.26028.CrossRefPubMedPubMedCentral

173.

Giovannoni G. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult Scler Relat Disord. 2020;41:102135. https://doi.org/10.1016/j.msard.2020.102135.CrossRefPubMedPubMedCentral

174.

Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699–708. https://doi.org/10.1001/jamaneurol.2021.0688.CrossRefPubMed

175.

Abboud H, Zheng C, Kar I, Chen CK, Sau C, Serra A. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020;44:102249. https://doi.org/10.1016/j.msard.2020.102249.CrossRefPubMedPubMedCentral

176.

Khiali S, Khani E, Entezari-Maleki T. A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J Clin Pharmacol. 2020;60(9):1131–46. https://doi.org/10.1002/jcph.1693.CrossRefPubMedPubMedCentral

177.

Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753–18. https://doi.org/10.1128/mBio.01753-18.

178.

Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, et al. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: retrospective cohort study. PLoS One. 2021;16(12):e0261113. https://doi.org/10.1371/journal.pone.0261113.CrossRefPubMedPubMedCentral

179.

van Kempen ZLE, Wieske L, Stalman EW, Kummer LYL, van Dam PJ, Volkers AG, et al. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: to wait and repopulate? Mult Scler Relat Disord. 2022;57:103416. https://doi.org/10.1016/j.msard.2021.103416.CrossRefPubMed

180.

Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778–88. https://doi.org/10.1016/S2665-9913(21)00222-8.CrossRefPubMedPubMedCentral

181.

Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed 15 Apr 2023.

182.

Hoffmann-La Roche Limited. https://pdf.hres.ca/dpd_pm/00056524.PDF. Date of initial approval 1 June 2020. Accessed 19 Mar 2023.

183.

Alexion Pharma GmbH. https://alexion.com/documents/ultomiris_product_monograph_approved_english. Date of initial authorization 28 Aug 2019 [Amended 6 Jan 2023]. Accessed 19 Mar 2023.

184.

Yang Y, Chen L, Wu L, Yao J, Wang N, Su X, et al. Effective rituximab treatment in patients with neuromyelitis optica spectrum disorders compared with azathioprine and mycophenolate. Neurol Ther. 2022;11(1):137–49. https://doi.org/10.1007/s40120-021-00298-5.CrossRefPubMed

185.

Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020;46:102538. https://doi.org/10.1016/j.msard.2020.102538.CrossRefPubMedPubMedCentral

186.

Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019;93(18):e1732–41. https://doi.org/10.1212/WNL.0000000000008394.CrossRefPubMedPubMedCentral

187.

Burton JM, Duggan P, Costello F, Metz L, Storek J. A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. Mult Scler Relat Disord. 2021;53:102990. https://doi.org/10.1016/j.msard.2021.102990.CrossRefPubMed

188.

• Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult Scler. 2015;21(2):189–97. https://doi.org/10.1177/1352458514541978. An elegant summary of case series and learning points from initial efforts to trial bone marrow transplantation in NMOSD.CrossRefPubMed

189.

Hoay KY, Ratnagopal P. Autologous hematopoietic stem cell transplantation for the treatment of neuromyelitis optica in Singapore. Acta Neurol Taiwan. 2018;27(1):26–32.PubMed

190.

Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. Bone Marrow Transplant. 2020;55(10):1928–34. https://doi.org/10.1038/s41409-020-0810-z.CrossRefPubMed

191.

Nabizadeh F, Masrouri S, Sharifkazemi H, Azami M, Nikfarjam M, Moghadasi AN. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J Clin Neurosci. 2022;105:37–44. https://doi.org/10.1016/j.jocn.2022.08.020.CrossRefPubMed

192.

Khan TR, Zimmern V, Aquino V, Wang C. Autologous hematopoietic stem cell transplantation in a pediatric patient with aquaporin-4 neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2021;50:102852. https://doi.org/10.1016/j.msard.2021.102852.CrossRefPubMed

193.

Matiello M, Pittock SJ, Porrata L, Weinshenker BG. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol. 2011;68(7):953–5. https://doi.org/10.1001/archneurol.2011.38.CrossRefPubMed

194.

Peng F, Qiu W, Li J, Hu X, Huang R, Lin D, et al. A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. Neurologist. 2010;16(6):375–8. https://doi.org/10.1097/NRL.0b013e3181b126e3.CrossRefPubMed

195.

Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N, et al. Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: a pilot, 2-year observational study. CNS Neurosci Ther. 2016;22(8):677–85. https://doi.org/10.1111/cns.12559.CrossRefPubMedPubMedCentral

196.

Ceglie G, Papetti L, Valeriani M, Merli P. Hematopoietic stem cell transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): state-of-the-art and future perspectives. Int J Mol Sci. 2020;21(15):5304. https://doi.org/10.3390/ijms21155304.CrossRefPubMedPubMedCentral

197.

Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 2014;28(1):230–3. https://doi.org/10.1038/leu.2013.240.CrossRefPubMed

198.

Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–14. https://doi.org/10.1056/NEJMoa2201904.CrossRefPubMed

199.

Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944. https://doi.org/10.1097/MD.0000000000015944.CrossRefPubMed

200.

Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol. 2017;74(8):1010–2. https://doi.org/10.1001/jamaneurol.2017.1336.CrossRefPubMedPubMedCentral

201.

Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, et al. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel). 2020;12(9):2540. https://doi.org/10.3390/cancers12092540.

202.

Katz Sand I, Fabian MT, Telford R, Kraus TA, Chehade M, Masilamani M, et al. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018;5(2):e441. https://doi.org/10.1212/NXI.0000000000000441.CrossRefPubMedPubMedCentral

203.

Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e5. https://doi.org/10.1212/NXI.0000000000000005.CrossRefPubMedPubMedCentral

204.

Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol. 2011;7(3):115–27. https://doi.org/10.3988/jcn.2011.7.3.115.CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2023

How do sleep patterns affect neurodevelopment in epilepsy?

Polypharmacy in multiple sclerosis

Measuring Pathology in Patients with Multiple Sclerosis Using Positron Emission Tomography

Cognitive Aspects of COVID-19

Trigeminal autonomic cephalalgias and neuralgias in children and adolescents

Cognitive interventions for neurodegenerative disease